Relapsing multiple sclerosis (RMS) is a chronic disease of the central nervous system (CNS) characterized by episodes or attacks (relapse) of neurologic dysfunction, which occur over many years. Onset typically occurs between the ages of 20 and 40 years.
Evidence suggests that RMS is an autoimmune disease that causes inflammation and damage in the central nervous system It is the most common disabling neurological disease of young adults. Many patients develop progressive disability, with or without occasional relapses, minor remissions, and plateaus. Meridian is conducting a clinical trial for an investigational medication for RMS.
- Must be age 18 to 55
- Must be diagnosed with RMS
- Must have at least 1 documented relapse within the past year, or 2 documented relapses within the previous 2 years, or 1 documented Gd-enhancing brain lesion on an MRI scan within the past year
- May receive compensation for time and travel
- Do not need insurance to join this study
For more information, complete the form on this page. After you submit your information, a Meridian enrollment specialist will call you to talk about the study. There is no obligation to join — you can decide if the study is right for you.
You can also talk to a Meridian enrollment specialist about this study by calling (912) 354-7676.
Submit your information
Meridian Clinical Research
6602 Waters Avenue, Building C
Savannah, GA 31406
Founded in 1999 in Omaha, NE, Meridian studies the safety and effectiveness of new medicines, devices, and treatments. Its mission is to enrich lives by providing quality, compassionate care to patients and unparalleled clinical research services. Clinical studies help scientists develop life-changing medicines, but it starts with you — participation makes it all possible. For more than 20 years, thousands of patients have trusted Meridian because of our focus on creating a positive patient experience.